Hair Loss in Men and Women: Different Causes, Different Approaches - A Clinical Analysis

Noticing a widening part, a receding hairline, or more hair collecting in the shower drain raises an immediate question: why is this happening? Hair loss is not a single condition with a single answer. Patterns, timing, hormonal drivers, and effective management paths differ considerably between men and women, and understanding those distinctions is the foundation of any informed response. Androgenetic alopecia (AGA) alone affects more than 50 million men and 30 million women in the United States. 1 Globally, more than 80 million people experience pattern hair loss, with roughly a one-in-two chance of being affected by the time an individual reaches their 50s. 2

The Biology of Hair Growth: A Shared Foundation

Every hair on the scalp follows a continuous cycle consisting of four phases: anagen (active growth), catagen (transition), telogen (resting), and exogen (active shedding). In a healthy individual, anagen lasts two to seven years, and approximately 85 to 90 percent of scalp hairs are in this phase at any given time. 3 The duration of the anagen phase largely determines maximum hair length and density. Disruption at any stage - whether by hormonal signaling, physical stress, or immune activity - produces different patterns of shedding or thinning. Dermatologists broadly categorize hair loss into scarring alopecias, which permanently destroy the follicle, and non-scarring alopecias, which leave the follicle structurally intact and therefore potentially reversible. 4

What is physically occurring in most progressive hair loss cases is follicle miniaturization, not follicle death. Susceptible follicles shrink progressively under hormonal signaling, producing progressively finer and shorter strands, and the anagen phase shortens so that hairs never reach their previous length. Because miniaturized follicles remain biologically present, early intervention can still stimulate them - a key reason why timing matters in treatment planning. 5

Male Pattern Hair Loss: DHT, Genetics, and Predictable Progression

In men, androgenetic alopecia accounts for approximately 95 percent of all hair loss cases. 6 The primary hormonal driver is dihydrotestosterone (DHT), a potent derivative of testosterone produced by the enzyme 5-alpha-reductase. DHT binds to androgen receptors in genetically susceptible follicles - concentrated at the temples, frontal hairline, and crown - causing them to miniaturize over successive growth cycles. Crucially, the process is driven by follicle sensitivity to DHT, not by elevated DHT levels per se. 7 The follicles at the back and sides of the scalp are genetically resistant and are typically spared, which explains the characteristic distribution seen in male pattern baldness.

Onset can occur surprisingly early. Approximately 20 percent of men begin balding by age 20, 30 percent by age 30, and roughly half of all men have experienced noticeable hair loss by age 50. 8 Progression is assessed clinically using the Hamilton-Norwood scale, which maps recession from the temples and thinning at the crown through to more extensive baldness. Family history on both maternal and paternal lines contributes to genetic risk, and multiple genes are involved, making predictability imperfect at the individual level. 9

Female Pattern Hair Loss: A More Complex Hormonal Picture

Female pattern hair loss (FPHL), also classified as female androgenetic alopecia, affects nearly 50 percent of women during their lifetime, representing the most prevalent form of chronic hair loss in this population. 10 Despite this high incidence, FPHL remains underdiagnosed and undertreated, with significant psychosocial consequences including diminished self-esteem, impaired social functioning, and reduced quality of life that clinical research shows often exceed impacts observed in men. Studies report that 29 percent of women experiencing hair loss report symptoms of depression, while 63 percent cite career-related issues stemming from their condition. 11

The hormonal picture in women is more multifactorial than in men. Androgens promote follicular miniaturization through progressive shortening of the anagen phase, while estrogens may provide protective effects - a dynamic that explains why hair loss accelerates around menopause, when estrogen levels decline. 12 Conditions such as polycystic ovary syndrome (PCOS) and thyroid dysfunction can further disrupt normal hair growth patterns. Unlike male pattern loss, FPHL typically presents as diffuse thinning across the crown and a widening part, with the frontal hairline usually preserved. Progression is assessed using the Ludwig scale rather than the Norwood scale. 13

Secondary Causes That Affect Both Sexes Differently

Beyond androgenetic alopecia, several secondary causes contribute substantially to clinical hair loss - and their relative frequency differs between men and women. Telogen effluvium (TE) is a reactive shedding condition in which follicles are pushed prematurely into the resting phase by a triggering event, typically appearing two to four months after that event. Common triggers include severe illness, major surgery, childbirth, rapid weight loss, and extreme psychological stress. 14 Unlike AGA, the follicles are not damaged in TE, and hair density typically recovers within six to twelve months once the trigger is removed - though chronic TE can persist if the underlying stressor continues. Women are disproportionately affected due to pregnancy, postpartum hormonal shifts, and the higher prevalence of iron deficiency anemia, all of which can initiate or sustain telogen effluvium. 15

Alopecia areata is an autoimmune condition in which the immune system attacks hair follicles, producing sudden patchy hair loss that can affect the scalp, eyebrows, eyelashes, and body hair. It can progress to alopecia totalis (complete scalp loss) or alopecia universalis (total body hair loss) in more severe cases. 16 Traction alopecia, caused by hairstyles that pull chronically on the hair, is another non-genetic cause seen more frequently in women. Scalp inflammation conditions such as seborrheic dermatitis can also contribute to shedding and thinning, and managing the underlying scalp condition is an integral part of addressing associated hair loss. 17

Evidence-Based Treatment Approaches: Where the Paths Diverge

For men, finasteride - a 5-alpha-reductase inhibitor that reduces DHT production - is a standard prescription option that demonstrably slows the progression of androgenetic alopecia. Minoxidil, available in topical and oral formulations, stimulates hair growth through mechanisms independent of DHT. 18 For women, topical minoxidil remains the only FDA-approved pharmaceutical treatment for FPHL. Off-label options include low-dose oral minoxidil, spironolactone as an anti-androgen agent, and 5-alpha-reductase inhibitors such as finasteride and dutasteride in carefully selected non-pregnant patients. 19 Transplanted hair using follicular unit extraction (FUE) is considered permanent, but continued medical therapy is generally required to protect non-transplanted follicles from ongoing DHT-mediated miniaturization. 20

Diagnosis, Systemic Evaluation, and Realistic Expectations

Because hair loss is a symptom rather than a standalone diagnosis, clinical evaluation is the necessary first step before any treatment is initiated. For men presenting with a typical pattern of recession and crown thinning, diagnosis is often straightforward on clinical examination. For women, the differential diagnosis is broader and more complex, encompassing telogen effluvium, diffuse alopecia areata, scarring alopecias, and androgenetic alopecia - conditions that can present with visually similar symptoms but require entirely different treatment approaches. 21 Diagnostic tools include trichoscopy, pull testing, and trichometric measurements to assess hair density and miniaturization patterns. Blood tests to evaluate thyroid function, iron stores, and androgen levels are frequently indicated in women. 22

Realistic expectations are essential for anyone entering hair loss management. AGA is a chronic, progressive condition and most treatments slow progression or partially restore density rather than fully reversing established loss. Early evaluation by a dermatologist improves the probability of slowing hair loss and preserving existing follicle function - once follicles pass a miniaturization threshold, response to treatment diminishes substantially. 23 Additionally, AGA in women may carry broader endocrine implications: in selected cases, particularly where androgen levels are elevated or PCOS is suspected, targeted screening for underlying endocrinologic abnormalities is warranted as part of comprehensive management. 24

Sources

1. Cincinnati.com / USA TODAY - How does hair loss differ between men and women? (March 5, 2026)
2. Iluka Medical Australia - Hair Loss in Men and Women: What Every Australian Should Know
3. DermaVue - What Causes Hair Fall in Men and Women: Dermatologist Guide
4. MyHairline.ai - What causes hair loss: every major reason explained (July 9, 2026)
5. Iluka Medical Australia - Hair Loss in Men and Women: What Every Australian Should Know
6. Highland Longevity - Hair Loss: Complete Evidence-Based Guide
7. Curekey - Causes of Hair Loss: Genetic, Hormonal, Medical, and More
8. Harvard Health - Treating hair loss in men: What works? (March 25, 2026)
9. Smart Salem - Genetic hair loss: what is it, and can it be reversed?
10. American Journal of Clinical Dermatology / Springer - Androgenetic Alopecia in Women: A Narrative Review (Vol. 27, 2026)
11. Charles Medical Group - Hair Loss Women's Thinning Solutions (February 25, 2026)
12. American Journal of Clinical Dermatology / Springer - Androgenetic Alopecia in Women: A Narrative Review (Vol. 27, 2026)
13. Jurnal Biologi Tropis - Androgenic Alopecia: A Comprehensive Literature Review (Vol. 25, 2025)
14. MyHairline.ai - Telogen effluvium vs androgenetic alopecia: how to tell them apart (July 9, 2026)
15. IPAL Clinic - Hair Loss in Men vs Women: Causes and Treatments
16. Doctronic - Understanding Hair Loss: Causes, Symptoms, and Solutions (March 15, 2026)
17. American Academy of Dermatology - Traction Alopecia and Seborrheic Dermatitis references
18. Mayo Clinic - Hair Loss: Diagnosis and Treatment
19. American Journal of Clinical Dermatology / Springer - Androgenetic Alopecia in Women: A Narrative Review (Vol. 27, 2026)
20. Highland Longevity - Hair Loss: Complete Evidence-Based Guide
21. Acibadem International - Hair Loss in Men and Women: Causes and Treatment Choices (June 9, 2026)
22. Abby Health - Female Hair Loss: Causes, Treatments, and What Actually Works (April 18, 2026)
23. Acibadem International - Alopecia Treatment: How Different Types Are Managed (July 9, 2026)
24. Canadian Diabetes and Endocrinology Today - Androgenetic Alopecia: Pathogenesis, Evaluation, and Management